[Market In] With Four Months Left Until the End of Their Terms… Six Directors of KoreaZinc Face Suspension
MBK and Youngpoong File for a Preliminary Injunction After Winning First-Instance Ruling to Overturn Shareholders’ Meeting Resolution
Request to Appoint Acting CEO and Acting Audit Committee Member Also Filed
If All Claims Are Upheld, Board Composition Could Be Reversed
[Edaily Marketin Hur Jieun Reporter] KoreaZinc(010130) The management control dispute is escalating into a battle for control of the board of directors. This follows a request for a preliminary injunction filed by MBK Partners and Youngpoong, seeking to suspend the duties of six KoreaZinc directors appointed at last year’s annual general meeting of shareholders. Since the terms of these directors expire in March of next year, observers interpret this as a strategic move to reshape the board’s composition before a final ruling is issued in the main lawsuit.
If the preliminary injunction is granted in full, the current voting dynamics on the board—where Chairman Choi’s faction holds the upper hand—could be reversed, making this a potential turning point in the management control dispute.
According to the Financial Supervisory Service’s electronic disclosure system on the 19th, MBK and Youngpoong filed a motion for a preliminary injunction against six directors of KoreaZinc, seeking to suspend their duties and appoint acting directors. This comes just four days after they won the first-instance trial at the Seoul Central District Court on the 12th regarding the lawsuit to annul the resolutions of the 2025 Annual General Meeting of Shareholders.
The provisional injunction targets a total of six individuals: CEO Park Ki-deok and outside directors Kwon Soon-beom, Kim Bo-young, James Andrew Murphy, Jeong Da-mi, and Seo Dae-won, all of whom were appointed at the regular shareholders’ meeting last March. All of them are classified as allies of Chairman Choi. MBK and Youngpoong requested that these individuals be suspended from their duties as directors until the ruling in the lawsuit to annul the resolutions of the relevant shareholders’ meeting becomes final. The request also included a call to suspend CEO Park from his duties as CEO and outside directors Kwon Soon-beom, Kim Bo-young, and Seo Dae-won from their duties as members of the Audit Committee.
In addition to the suspension of duties, this preliminary injunction petition also includes a request to appoint acting CEO and acting members of the Audit Committee. This is interpreted as a measure to ensure that there are no gaps in the company’s day-to-day business operations or the functioning of the Audit Committee even if the directors’ duties are suspended. Whether acting officers are actually appointed and the specific scope of their authority may depend on the court’s decision.
If the preliminary injunction is granted in full, significant changes are expected in the composition of KoreaZinc’s board of directors. Currently, the board consists of 19 members: 12 aligned with Chairman Choi and 7 aligned with MBK and Youngpoong. If the execution of duties by six directors aligned with Chairman Choi is suspended and the acting director is not granted voting rights on the board, the composition of directors able to exercise voting rights will shift to six from Chairman Choi’s side and seven from the Youngpoong and MBK side. This effectively reverses the existing 12-to-7 ratio to 6-to-7.
A key point to note is the expiration date of the directors’ terms. The six directors subject to suspension were all appointed for a two-year term at the regular shareholders’ meeting in March 2025, and their terms are scheduled to end next March. It is reported that the MBK and Youngpoong side has emphasized that even if KoreaZinc appeals the first-instance ruling, there is a high likelihood that the terms of these directors will expire before the appellate court issues its decision. Their argument is that if they win the main lawsuit but the directors’ terms end before the ruling becomes final, the practical effect of the legal remedy could be lost.
On the other hand, KoreaZinc is expected to counter this argument based on the Supreme Court’s ruling in the previous preliminary injunction case. KoreaZinc has maintained the position that the restriction on voting rights for cross-shareholdings through its Australian affiliate was lawful during last year’s annual general meeting. The company argues that since the Supreme Court did not accept the claims made by MBK and Youngpoong in the earlier preliminary injunction regarding the exercise of voting rights, there is room for legal dispute regarding the first-instance ruling in this main lawsuit as well.
Depending on the outcome of the preliminary injunction, changes could occur in KoreaZinc’s major management decisions. Under the Commercial Act, the board of directors has the authority to decide on major management matters, such as the disposal of significant assets and large-scale borrowing. There is speculation that if the MBK and Youngpoong side secures a numerical majority on the board, the burden on Chairman Choi’s side could increase during the deliberation and voting processes for future new investments, fundraising, and major management agenda items.
A legal expert explained, “The key to this preliminary injunction will be the extent to which the court recognizes the need to preserve rights in accordance with the first-instance ruling,” adding, “Since the subject matter of this suspension of duties injunction differs from that of the previous one, the prior decision does not necessarily determine the outcome of this case.”
Korea Digital Exchange, which operates the digital asset (virtual asset) exchange Flybit, has taken steps to strengthen anti-money laundering measures and user protection. Korea Digital Asset Exchange…
NamyangDairyProducts(003920)’s protein brand “TakeFit” saw its cumulative sales for the third quarter of this year increase by 48.3% compared to the same period last year. Analysts attribute this grow…
Coreline Soft Co., Ltd.(384470)is set to showcase medical artificial intelligence (AI) technology in the U.S. that analyzes information related to lung and cardiovascular diseases from a single chest …